Cargando…
FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032849/ https://www.ncbi.nlm.nih.gov/pubmed/33837193 http://dx.doi.org/10.1038/s41392-021-00590-8 |
| _version_ | 1783676293609422848 |
|---|---|
| author | He, Xuemei Wang, Manni Wu, Min |
| author_facet | He, Xuemei Wang, Manni Wu, Min |
| author_sort | He, Xuemei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8032849 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80328492021-04-09 FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 He, Xuemei Wang, Manni Wu, Min Signal Transduct Target Ther Research Highlight Nature Publishing Group UK 2021-04-09 /pmc/articles/PMC8032849/ /pubmed/33837193 http://dx.doi.org/10.1038/s41392-021-00590-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Research Highlight He, Xuemei Wang, Manni Wu, Min FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title | FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title_full | FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title_fullStr | FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title_full_unstemmed | FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title_short | FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 |
| title_sort | fcγriib blockage: a promising immunotherapy target for severe covid-19 |
| topic | Research Highlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032849/ https://www.ncbi.nlm.nih.gov/pubmed/33837193 http://dx.doi.org/10.1038/s41392-021-00590-8 |
| work_keys_str_mv | AT hexuemei fcgriibblockageapromisingimmunotherapytargetforseverecovid19 AT wangmanni fcgriibblockageapromisingimmunotherapytargetforseverecovid19 AT wumin fcgriibblockageapromisingimmunotherapytargetforseverecovid19 |